Study on the Safety of Pumitamig Alone or with Ipilimumab for Advanced Liver Cancer
Sponsor: Bristol-Myers Squibb
Sponsor score: 60
ClinicalTrials ID:NCT07291076
This clinical trial is testing the safety of a new drug, Pumitamig, used alone or with another drug, Ipilimumab, in patients with advanced liver cancer that cannot be removed by surgery.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The goal of this study is to find out if the new drug Pumitamig is safe for patients with advanced liver cancer, either when used by itself or together with another drug called Ipilimumab. This study is for patients who are receiving their first treatment for liver cancer that cannot be surgically removed.
Eligibility Criteria
Inclusion Criteria
- Participants must have a histologically confirmed diagnosis of locally advanced or unresectable Hepatocellular Carcinoma (HCC).
- Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Participants must have no prior systemic therapy for advanced/ unresectable HCC.
- Participants must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Exclusion Criteria
- Participants must not have significant bleeding or coagulation disorders or other obvious bleeding risk evidence.
- Participants must not have an organ transplant or autoimmune disease.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Local Institution - 0070 | 90064 | Los Angeles | California |
| Local Institution - 0107 | 60611 | Chicago | Illinois |
| John Theurer Cancer Center at Hackensack University Medical Center | 07601-2191 | Hackensack | New Jersey |
| Local Institution - 0100 | 11501 | Mineola | New York |
| Providence Portland Medical Center | 97213 | Portland | Oregon |
| Providence St. Vincent Medical Center | 97225 | Portland | Oregon |
| Tennessee Oncology | 37203 | Nashville | Tennessee |
| Vanderbilt University Medical Center | 37232 | Nashville | Tennessee |
| Local Institution - 0083 | 98109-1024 | Seattle | Washington |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.